Vanda Pharmaceuticals Stock Rallies on FDA Filing

Core Viewpoint - Vanda Pharmaceuticals Inc. has filed a Biologics License Application with the FDA for isidolimab, an antibody-based treatment for pustular psoriasis, leading to a 2.2% increase in share price to $7.06 [1] Stock Performance - The stock has surpassed the $7 level, reaching a two-year high of $7.25, and has increased over 47% year-to-date [2] - The stock broke through resistance at $5.50 earlier this month after being below this level for November [2] Short Interest and Options Activity - Short interest constitutes 8.5% of the total float, with 4.6 million shares sold short, and bearish bets have risen nearly 20% in the last two weeks [3] - At the current trading pace, it would take nearly seven days for short sellers to cover their positions [3] - Options activity shows 2,267 calls traded, which is double the average volume, compared to only 65 puts, with the most popular contract being the January 16, 2026 8-strike call [3]